{
    "nctId": "NCT01194427",
    "briefTitle": "A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer",
    "officialTitle": "A Multi-Institutional Phase II Study Evaluating Surrogate Biomarkers of Response to Short Term Oral Vorinostat and Tamoxifen in Women With Newly Diagnosed Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Changes in Markers of Proliferation Prior to and After Study Drug Administration",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage I-III invasive breast cancer\n* Awaiting surgery or neoadjuvant treatment\n* ECOG performance status 0, 1 or 2\n* Adequate organ function\n* Prior use of hormone contraception or replacement therapy must have been discontinued at least 30 days prior to diagnostic biopsy (unless participant is willing to undergo an additional biopsy for the study)\n\nExclusion Criteria:\n\n* Prior or current treatment of any kind for the current breast cancer\n* Current use of any other investigational drugs\n* Uncontrolled or active infection, congestive heart failure, cardiac arrythmia, or psychiatric illness",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}